Cellectis S.A. (ALCLS.PA)
EUR 1.35
(0.15%)
EUR 1.35
(0.15%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -97.3 Million USD | -8.52% |
| 2022 | -89.66 Million USD | -4.95% |
| 2021 | -85.43 Million USD | 0.0% |
| 2020 | -85.43 Million USD | 30.85% |
| 2019 | -123.55 Million USD | -17.57% |
| 2018 | -105.09 Million USD | -13.43% |
| 2017 | -92.65 Million USD | -44.85% |
| 2016 | -63.96 Million USD | -109.51% |
| 2015 | -30.52 Million USD | -378.67% |
| 2014 | -6.37 Million USD | 92.09% |
| 2013 | -80.62 Million USD | -208.43% |
| 2012 | -26.13 Million USD | -3.29% |
| 2011 | -25.3 Million USD | -65.97% |
| 2010 | -15.24 Million USD | -12.99% |
| 2009 | -13.49 Million USD | -181.31% |
| 2008 | -4.79 Million USD | 38.35% |
| 2007 | -7.78 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -21.29 Million USD | 28.01% |
| 2024 Q2 | -17.21 Million USD | 19.17% |
| 2023 Q3 | -20.67 Million USD | 12.63% |
| 2023 FY | -97.3 Million USD | -8.52% |
| 2023 Q4 | -29.57 Million USD | -43.09% |
| 2023 Q1 | -23.43 Million USD | -313.98% |
| 2023 Q2 | -23.65 Million USD | -0.97% |
| 2022 Q4 | -5.66 Million USD | 82.93% |
| 2022 Q1 | -35.24 Million USD | 10.0% |
| 2022 FY | -89.66 Million USD | -4.95% |
| 2022 Q2 | -34.07 Million USD | 3.32% |
| 2022 Q3 | -33.16 Million USD | 2.69% |
| 2021 Q3 | -42.36 Million USD | -13.04% |
| 2021 Q2 | -37.48 Million USD | -88.28% |
| 2021 Q4 | -39.16 Million USD | 7.56% |
| 2021 FY | -85.43 Million USD | 0.0% |
| 2021 Q1 | -19.9 Million USD | 49.17% |
| 2020 FY | -85.43 Million USD | 30.85% |
| 2020 Q1 | 14.41 Million USD | 137.44% |
| 2020 Q2 | -33.03 Million USD | -329.19% |
| 2020 Q3 | -29.35 Million USD | 11.13% |
| 2020 Q4 | -39.16 Million USD | -33.42% |
| 2019 Q2 | -35.12 Million USD | -51.94% |
| 2019 Q3 | -26.65 Million USD | 24.13% |
| 2019 FY | -123.55 Million USD | -17.57% |
| 2019 Q1 | -23.11 Million USD | 21.0% |
| 2019 Q4 | -38.49 Million USD | -44.44% |
| 2018 FY | -105.09 Million USD | -13.43% |
| 2018 Q4 | -29.26 Million USD | -1.25% |
| 2018 Q3 | -28.9 Million USD | -33.22% |
| 2018 Q2 | -21.69 Million USD | 12.87% |
| 2018 Q1 | -24.9 Million USD | 10.3% |
| 2017 Q3 | -25.7 Million USD | -24.55% |
| 2017 Q4 | -27.76 Million USD | -8.01% |
| 2017 FY | -92.65 Million USD | -44.85% |
| 2017 Q2 | -20.63 Million USD | -4.13% |
| 2017 Q1 | -19.81 Million USD | -0.04% |
| 2016 Q2 | -11.14 Million USD | 51.82% |
| 2016 Q4 | -19.8 Million USD | -52.81% |
| 2016 Q3 | -12.96 Million USD | -16.33% |
| 2016 FY | -63.96 Million USD | -109.51% |
| 2016 Q1 | -23.13 Million USD | -1852.78% |
| 2015 Q2 | -13.6 Million USD | -252.98% |
| 2015 FY | -30.52 Million USD | -378.67% |
| 2015 Q1 | -3.85 Million USD | -766.17% |
| 2015 Q4 | 1.31 Million USD | 108.72% |
| 2015 Q3 | -15.13 Million USD | -11.25% |
| 2014 Q1 | -3.44 Million USD | 39.19% |
| 2014 FY | -6.37 Million USD | 92.09% |
| 2014 Q4 | -444.83 Thousand USD | -385.4% |
| 2014 Q3 | 155.86 Thousand USD | 104.55% |
| 2014 Q2 | -3.42 Million USD | 0.64% |
| 2013 Q3 | -5.56 Million USD | 43.68% |
| 2013 Q4 | -5.66 Million USD | -1.75% |
| 2013 FY | -80.62 Million USD | -208.43% |
| 2013 Q1 | -9.74 Million USD | -82.37% |
| 2013 Q2 | -9.88 Million USD | -1.46% |
| 2012 Q4 | -5.34 Million USD | -5.1% |
| 2012 FY | -26.13 Million USD | -3.29% |
| 2012 Q3 | -5.08 Million USD | 0.0% |
| 2011 FY | -25.3 Million USD | -65.97% |
| 2010 FY | -15.24 Million USD | -12.99% |
| 2009 FY | -13.49 Million USD | -181.31% |
| 2008 FY | -4.79 Million USD | 38.35% |
| 2007 FY | -7.78 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -2751.758% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 23.61% |
| Adocia SA | -17.62 Million EUR | -452.162% |
| Aelis Farma SA | -6.46 Million EUR | -1405.99% |
| Biophytis S.A. | -14.33 Million EUR | -578.867% |
| Advicenne S.A. | -6.45 Million EUR | -1406.923% |
| genOway Société anonyme | 2.06 Million EUR | 4811.286% |
| IntegraGen SA | -183.77 Thousand EUR | -52847.706% |
| Medesis Pharma S.A. | -4.22 Million EUR | -2200.642% |
| Neovacs S.A. | -6.9 Million EUR | -1308.633% |
| NFL Biosciences SA | -4.43 Million EUR | -2096.225% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -12402.875% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -3001.502% |
| Sensorion SA | -22.31 Million EUR | -336.124% |
| Theranexus Société Anonyme | -7.64 Million EUR | -1172.974% |
| TME Pharma N.V. | -5.62 Million EUR | -1630.121% |
| Valbiotis SA | -7.16 Million EUR | -1258.966% |
| TheraVet SA | -2.17 Million EUR | -4373.431% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | -379.604% |
| DBV Technologies S.A. | -85.24 Million EUR | -14.142% |
| Genfit S.A. | -26.58 Million EUR | -266.072% |
| GeNeuro SA | -14.35 Million EUR | -577.718% |
| Innate Pharma S.A. | -12.66 Million EUR | -668.032% |
| Inventiva S.A. | -102.7 Million EUR | 5.264% |
| MaaT Pharma SA | -19.94 Million EUR | -387.901% |
| MedinCell S.A. | -20.97 Million EUR | -363.851% |
| Nanobiotix S.A. | -26.77 Million EUR | -263.352% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | -323.31% |
| Poxel S.A. | -28.76 Million EUR | -238.277% |
| GenSight Biologics S.A. | -29.69 Million EUR | -227.66% |
| Transgene SA | -30.01 Million EUR | -224.21% |
| Valneva SE | -82.08 Million EUR | -18.535% |